Compare GSK plc (GSK) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Remitly Global Inc — how do they compare? GSK plc trades at $52.69 (market cap $101.34B), while Remitly Global Inc trades at $25.53 (market cap $5.26B). The key difference: GSK plc is far larger — about 19.3× Remitly Global Inc's market cap, and GSK plc pays a 3.49% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals.
| GSK | RELY | |
|---|---|---|
Market Cap | $101.34B | $5.26B |
Sector | Health | Technology |
52-Week High | $61.18 | $24.96 |
52-Week Low | $36.20 | $12.20 |
Enterprise Value | $121.95B | $4.65B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
RELY stock trades at $25.57, up 8.72% in the last 24 hours, showing strong momentum. The company demonstrates accelerating revenue growth from $654M in 2022 to $1.64B in 2025, with net income turning positive at $67.93M. Technical indicators show bullish momentum with the current price near resistance at $26. Recent expansion into UAE and Canadian markets positions the company for continued international growth.
RELY presents a compelling growth story with improving profitability and strong analyst support (92% buy ratings). However, elevated valuation multiples (P/E 52) and competitive pressures in the remittance space warrant caution. The stock's upside potential to the $27.40 consensus target appears reasonable given accelerating revenue and expanding margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
